Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data ASSEMBLY BIOSCIENCES, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
9.02
14.8
16
79.1
6.25
0
7.16
28.5
72.3
Research and development
33.1
44.2
72.7
85.8
107
68.5
70
48.9
55.9
64.8
General and administrative
12.2
17
34.8
32.9
37.1
28.8
24.1
22.9
18
19.6
Operating expenses
61.2
108
119
144
139
94.1
71.8
73.9
84.4
Operating income
-45.3
-52.2
-92.7
-103
-64.8
-133
-94.1
-64.6
-45.4
-12.1
Interest income
1.54
0.98
3.08
4.31
2.62
0.3
1.02
3.45
5.57
6
Other non-operating income
0.4
0.37
3.08
4.31
2.62
0.3
1.02
3.45
5.57
6
Pre-tax income
-44.9
-51.9
-89.7
-98.4
-62.2
-132
-93.1
-61.2
-39.8
-6.12
Income tax
-0.62
-9.05
1.1
-0.77
0
-2.53
0
0.03
0.33
0
Net income
-44.3
-42.8
-90.8
-97.6
-62.2
-130
-93.1
-61.2
-40.2
-6.12
EBITDA
-45.2
-52
-92.1
-102
-64.1
-132
-93.6
-64.2
-45.3
-12
EPS, basic
-30.89
-28.97
-47.84
-44.72
-21.04
-36.06
-23.08
-13.38
-6.69
-0.55
EPS, diluted
-30.89
-28.97
-47.84
-44.72
-21.04
-36.06
-23.08
-13.38
-6.69
-0.55
Shares, basic (weighted)
1.43
1.48
1.9
2.18
2.95
3.6
4.03
4.58
6
11.2
Shares, diluted (weighted)
1.43
1.48
1.9
2.18
2.95
3.6
4.03
4.58
6
11.2
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
28.6
82
41.5
46.7
59.4
45.6
52.4
19.8
38.3
58.5
Short-term investments
24.4
37.9
177
227
157
101
39.2
110
73.7
190
Receivables
0
2.27
2.43
3.37
1.23
0.34
0.94
0.04
0
0.97
Other current assets
0.61
0.9
1.99
5.36
6.85
7.24
4.41
3.5
3.42
5.47
Total current assets
53.6
123
223
283
224
154
97
134
116
255
Property, plant and equipment
0.21
0.86
0.56
1.83
1.6
1.14
0.74
0.39
0.28
0.22
Lease right-of-use assets
0
12
9.13
6.04
3.2
2.34
3.07
2.51
Goodwill
12.6
12.6
12.6
12.6
12.6
Intangible assets
29
29
Long-term investments
2.44
3.35
0
0
0
28
0
Other non-current assets
0.34
3.35
1.68
6.39
1.7
0.89
0.31
0.31
0.31
Total assets
98.1
169
268
340
283
191
102
137
119
258
Accounts payable
3.69
1.73
4.6
2.66
2.49
0.46
0.59
1.17
Accrued liabilities
4.75
6.14
9.68
8.29
12
6.86
7.32
5.74
6.86
7.75
Deferred revenue
0
45.8
5.1
6.41
30.9
37.6
36.9
Total current liabilities
7.12
13.5
18.5
24.4
24.4
16.1
16.3
39.2
47.8
48.8
Lease liabilities
0
9.08
6.73
3.33
0.1
1.12
2.63
2.06
Total liabilities
18.2
56.2
57.4
66.7
42.7
22.1
19.1
95.7
85.8
50.8
Paid-in capital
289
365
553
713
742
801
808
827
859
1,039
Retained earnings
-208
-251
-342
-439
-502
-631
-725
-786
-826
-832
Other comprehensive income
-0.6
-0.39
-0.35
-0.2
-0.27
-0.42
-0.8
-0.08
-0.21
-0.04
Shareholders' equity
79.9
113
211
273
241
169
82.7
41.1
33.4
207
Total equity
79.9
113
211
273
241
169
82.7
41.1
33.4
207
Total liabilities and equity
98.1
169
268
340
283
191
102
137
119
258
Shares outstanding
1.43
1.68
2.12
2.71
2.83
4
4.07
5.48
7.46
15.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-44.3
-42.8
-90.8
-97.6
-62.2
-130
-93.1
-61.2
-40.2
-6.12
Depreciation and amortization
0.08
0.22
0.64
0.49
0.69
0.47
0.5
0.45
0.13
0.13
Stock-based compensation
5.02
8.6
28.5
20.6
21.9
5.24
6.59
5.12
3.12
4.68
Deferred income tax
-0.62
-9.05
1.1
-0.77
0
-2.53
0
0
0
Change in receivables
0
-2.27
-0.16
-0.94
2.14
0.89
-0.61
0.9
0.04
-0.97
Change in payables
1
-0.24
1.57
-1.96
2.87
-1.94
-0.17
-2.03
0.12
0.59
Cash from operations
-34.9
1.86
-65
-84.1
-63
-93.4
-84.5
22.7
-51.1
-41.1
Capital expenditures
-0.15
-0.87
-0.34
-1.55
-0.47
-3.1
-0.1
-0.26
-0.03
-0.07
Acquisitions
0
Purchases of investments
-7.95
-48.2
-184
-281
-193
-160
-27.6
-134
-90.5
-230
Sales and maturities of investments
44.3
33.5
48.9
204
222
175
88
65
131
116
Cash from investing
36.2
-15.6
-135
-50.3
68.1
26.5
90.6
-69.1
40.2
-113
Stock issued
64.8
155
135
5.45
52.8
0.33
4.55
2.03
1.92
Cash from financing
0.15
67.2
160
140
7.6
53.1
0.61
13.8
29.4
175
Net change in cash
1.47
53.5
-40.6
5.26
12.7
-13.8
6.79
-32.6
18.5
20.1
Free cash flow
-35
1
-65.3
-85.6
-63.4
-96.5
-84.6
22.5
-51.1
-41.2
Income taxes paid
0
0.4
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $23.67 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-11.8%
Operating income / revenue.
EBITDA margin
-11.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-0.1%
Net income / revenue.
FCF margin
-51.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-51.4%
Cash from operations / revenue.
Return on equity (ROE)
-0.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-0.0%
Net income / average total assets.
Return on invested capital (ROIC)
-2.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
85.0%
Research and development expense / revenue.
Stock-based pay / revenue
8.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
0.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
153.5%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 5y
-1.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
519.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
35.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-3.0%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
116.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
36.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-1.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
86.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
40.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
30.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
14.0x
Current assets / current liabilities.
Quick ratio
13.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.97
Revenue / diluted weighted shares.
FCF per share
-$2.05
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.04
Cash from operations / diluted weighted shares.
Book value per share
$15.40
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
6.44x
Market cap / revenue.
P/B
1.58x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.58x
Market cap / tangible book value, when positive.
EV/Sales
2.16x
Enterprise value / revenue.
FCF yield
-8.0%
Free cash flow / market cap.
Earnings yield
-0.0%
Net income / market cap (the inverse of P/E).
What was ASSEMBLY BIOSCIENCES, INC.'s revenue in fiscal 2025?
ASSEMBLY BIOSCIENCES, INC. reported revenue of $72.3M for fiscal 2025, 153.5% higher than the year before.
Was ASSEMBLY BIOSCIENCES, INC. profitable in fiscal 2025?
No. It reported a net loss of $6.1M.
How much free cash flow did ASSEMBLY BIOSCIENCES, INC. generate in fiscal 2025?
Cash from operations of $41.1M minus capital expenditures of $66.0K left free cash flow of -$41.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.